Trending Now
Is today’s surge in Dermata Therapeutics (DRMA) justified ?
Dermata Therapeutics, Inc. (Nasdaq:DRMA) is making significant strides with its focus on medical and aesthetic skin conditions. Recently, Dermata announced the successful...
Janux Therapeutics Reports Breakthrough in Prostate Cancer Treatment with JANX007
In a significant development from San Diego, Janux Therapeutics, Inc. (NASDAQ: JANX) has released an update on its groundbreaking JANX007 clinical program,...
NovoCure Limited (NASDAQ: NVCR): Groundbreaking PANOVA-3 Trial Results Signal Hope for...
NovoCure Limited (NASDAQ: NVCR) achieved a major milestone with the announcement of positive results from its pivotal Phase 3 PANOVA-3 trial, conducted...
Popular News
Protagonist Therapeutics (NASDAQ: PTGX) Receives $25 Million Milestone Payment from Partnership...
Protagonist Therapeutics (NASDAQ: PTGX) has announced a $25 million milestone payment from its partnership with Janssen Biotech Inc. after dossing the third subject in...
MAKE IT MODERN
LATEST REVIEWS
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) Receive Letter From the...
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) announced that the Nasdaq Stock Department LLC's Listing Qualifications Department sent a staff determination letter...
MAKE IT MODERN
PERFORMANCE TRAINING
Y-mAbs Therapeutics Inc (YMAB) could be an acquisition target
Y-mAbs Therapeutics, Inc. (YMAB) opened at $4.39. With a bid of $5.10 x 2200 and an ask of $5.25 x 1400, the...
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Enters a Note Purchase Agreement And Prices $35 Million...
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has entered a note purchase agreement with Athyrium Capital Management-managed funds for around $100 million senior secured notes.
Financing offers...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Disclosed Its Findings on Its Latest Long COVID...
Tonix Pharmaceutical Holding Corporation (NASDAQ: TNXP) recently announced the findings of its recent experimental research that focused on 50,000 individuals that carried the prognosis...
Galecto Inc (NASDAQ: GLTO) Enrolls Patients in GULLIVER-2 Study
Galecto Inc (NASDAQ: GLTO) has enrolled patients for the second and third parts of its Phase Ib/IIa GB1211, GULLIVER-2 study. The company...
OSI Systems, Inc. (NASDAQ:OSIS) Bags $5 Million Order For The Supply Of Baggage Screening...
The commonwealth government of Australia awarded an order worth $5 million to OSI Systems, Inc. (NASDAQ:OSIS). As per the terms of the contract, OSI’s...
MAKE IT MODERN
POPULAR
